Evaluation of stem cell therapy efficacy in canine osteoarthritis: a randomized controlled trial

Project Abstract

This randomized controlled trial evaluated the efficacy of mesenchymal stem cell (MSC) therapy for treating osteoarthritis (OA) in dogs, comparing standardized intra-articular MSC administration to a conventional non-steroidal anti-inflammatory drug (NSAID) regimen over a 12-week period. A multicenter cohort of 120 client-owned dogs with radiographically and clinically confirmed elbow or stifle OA were enrolled and randomly assigned to MSC treatment or NSAID control, with stratification by joint affected and OA severity. The MSC group received a single intra-articular injection of autologous adipose-derived MSCs suspended in a platelet-rich plasma scaffold, followed by standardized rehabilitation. The control group received daily NSAID therapy (carprofen or firocoxib) for 12 weeks and the same rehabilitation protocol. Primary outcomes included validated owner-reported limb function scores (Canine Brief Pain Inventory and Liverpool Osteoarthritis in Dogs score), peak vertical force assessments via force plate analysis, and range of motion (ROM) measurements at baseline, 6 weeks, and 12 weeks. Secondary outcomes encompassed owner global assessment, lameness scores by blinded veterinarians, and serum inflammatory biomarkers (IL-6, TNF-?, and CRP). Safety endpoints monitored adverse events, joint effusion, and radiographic progression at 12 weeks. Results demonstrated that the MSC group achieved statistically significant improvements in owner-reported function scores compared with NSAID-treated dogs at both 6 and 12 weeks (p<0.01). Objective gait analysis showed greater increases in peak vertical force and higher limb use symmetry in the MSC cohort, with effect sizes indicating a clinically meaningful improvement in weight-bearing on the affected limb. ROM improved more in the MSC group, with reductions in joint stiffness reported by owners. Biochemical analyses revealed a significant reduction in systemic inflammatory markers in the MSC-treated dogs, suggesting a disease-modifying effect, while NSAID therapy primarily provided symptomatic relief. Blinded clinical assessments corroborated these findings, with fewer lameness visits and improved pain scores in the MSC group. Radiographic evaluation at 12 weeks indicated no progression of osteoarthritic changes in either group, though MRI subsample analysis suggested reduced synovitis and cartilage degradation markers in MSC-treated joints. Adverse events were infrequent and comparable between groups, with transient mild injection-site reactions in a minority of MSC-recipients and occasional GI upset in NSAID-treated dogs; no severe treatment-related complications occurred. Subgroup analyses indicated greater benefit of MSC therapy in skeletally mature dogs with moderate OA and in elbow OA compared to the stifle, though benefits persisted across subgroups. Kaplan-Meier-type time-to-improvement curves favored MSC therapy for achieving clinically meaningful thresholds in pain and function earlier than NSAID treatment. Multivariate modeling highlighted MSC administration as an independent predictor of improved functional outcomes after adjusting for age, weight, breed, and OA severity. The study supports MSC therapy as a promising disease-modifying approach for canine OA, providing durable functional gains, reduced inflammatory burden, and favorable safety, potentially redefining standard-of-care strategies for veterinary OA management pending long-term follow-up and cost-effectiveness analyses.

Project Overview

What This Project Is About

---

A plain-language overview of stem cell therapy for dogs with osteoarthritis, exploring whether this treatment can reduce pain and improve mobility compared with standard care. The project examines how stem cells might help joint tissues heal and reduce inflammation, using a controlled comparison to measure outcomes in dogs with similar conditions.

---

---

The Problem It Addresses

---

Osteoarthritis in dogs causes chronic pain and limited quality of life for pets and owners. Current treatments mainly manage symptoms rather than repair damaged joints, and long-term options vary in effectiveness. This project investigates whether stem cell therapy offers a safer, more effective option that could slow disease progression and improve function.

---

---

Objectives of the Project

---

1. Assess the impact of stem cell therapy on pain scores in dogs with osteoarthritis.
2. Evaluate changes in mobility and daily activity after treatment.
3. Compare outcomes with a control group receiving standard care.
4. Monitor safety and potential adverse effects.
5. Analyze cost-effectiveness and practical feasibility for clinical use.

---

---

What You Will Do Step by Step

---

1. Literature review to understand current treatments and stem cell approaches.
2. Select eligible dogs and obtain owner consent for participation.
3. Randomly assign dogs to stem cell therapy or standard care groups.
4. Administer treatment and establish a baseline for pain and function.
5. Collect follow-up data at set intervals using simple scoring scales and owner diaries.
6. Analyze data to compare outcomes between groups and check for safety signals.
7. Interpret results in the context of existing evidence and limitations.
8. Prepare a concise report with practical implications for clinicians and caretakers.

---

---

Expected Outcome

Expected to show whether stem cell therapy provides superior pain relief and mobility improvements over standard care, with acceptable safety. If effective, findings could support integrating stem cell options into veterinary practice and inform future larger trials.